Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Xenoport
About
XenoPort is a biopharmaceutical company that develops a portfolio of product candidates to treat neurological disorders.
- 251 - 500
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $15.87M
- Industries
- Biotechnology,Developer Platform,Pharmaceutical
- Founded date
- Jan 1, 1999
- Number Of Employee
- 251 - 500
- Operating Status
- Active
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 1, 2002 | Series B | $43.90M | 1 | — | — | Detail |
| Feb 1, 2000 | Series A | $15.87M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series B |
